Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics

Neoplasia

Volumn 11, Issue 9, 2009, Pages 874-881

  Ferretti, Stephane ^a   Allegrini, Peter R ^a   Becquet, Mike M ^a   McSheehy, Paul M J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CYCLOPHOSPHAMIDE; EPOTHILONE B; EVEROLIMUS; GEMCITABINE; IMATINIB; TUMOR MARKER; VATALANIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BERLIN DRUCKSEY IX RAT; BLOOD VOLUME; BREAST TUMOR; BROWN NORWAY RAT; C3H MOUSE; C57BL 6 MOUSE; CANCER CHEMOTHERAPY; CANCER INHIBITION; COLON TUMOR; CORRELATION ANALYSIS; CYTOSTASIS; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL NEOPLASM; FEMALE; FIBROSARCOMA; GLIOMA; HUMAN; HUMAN CELL; HYPOXIA; ISOGRAFT; MELANOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; OVARY TUMOR; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SOLID TUMOR; TISSUE PRESSURE; TREATMENT RESPONSE; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT; UTERINE CERVIX TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; EXTRACELLULAR FLUID; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; RATS; RATS, INBRED BN; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69249156004     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09554     Document Type: Article

References (25)

1. Jain RK (1994). Barrier to drug delivery in solid tumours. Sci Am 271 (1), 58-65.
2. Brown JM and Giaccia AJ (1998). The unique physiology of solid tumours: opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416.
3. Milosevic M, Fyles A, Hedley D, Pintilie M, Levin W, Manchul L, and Hill R (2001). Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumour oxygen measurements. Cancer Res 61 (17), 6400-6405.
4. Kristjansen PE, Boucher Y, and Jain RK (1993). Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res 53 (20), 4764-4766.
5. Podobnik B, Sersa G, and Miklavcic D (2001). Effect of hydralazine on interstitial fluid pressure in experimental tumours and in normal tissue. In Vivo 15 (5), 417-424.
6. Pietras K, Ostman A, Sjöquist M, Buchdunger E, Reed RK, Heldin CH, and Rubin K (2001). Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumours. Cancer Res 61, 2929-2934.
7. Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB, Sjöquist M, Ahlström H, Reed RK, and Rubin K (2003). Lowering of tumour interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J 17 (12), 1756-1758.
8. Ferretti S, Allegrini PR, O'Reilly T, Schnell C, Stumm M, Wartmann M, Wood J, and McSheehy PM (2005). Patupilone induced vascular disruption in orthotopic rodent tumour models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 11 (21), 7773-7784.
9. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145-147.
10. Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, Molokhia P, Attia K, Sullivan T, Kuter I, et al. (2005). Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancer in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 23, 1951-1961.
11. Rudin M, McSheehy PM, Allegrini PR, Rausch M, Baumann D, Becquet M, Brecht K, Brueggen J, Ferretti S, Schaeffer F, et al. (2005). PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo. NMR Biomed 18, 308-321.
12. 18F]- tracers in various experimental tumour models by PET imaging and identification of an early response biomarker for the novel microtubule stabiliser patupilone. Mol Imaging Biol [May 22, Epub ahead of print].
13. Eva A, Robbins KC, Andersen PR, Srinivasan A, Tronick SR, Reddy EP, Ellmore NW, Galen AT, Lautenberger JA, Papas TS, et al. (1982). Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature 295, 116-119.
14. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, and Poruchynsky MS (1997). Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272 (27), 17118-17125.
15. Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, McSheehy P, Wartmann M, and Ostman A (2003). STI571 enhances the therapeutic index of Epothilone B by a tumour-selective increase of drug uptake. Clin Cancer Res 9, 3779-3787.
16. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, et al. (2004). AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumour and antiangiogenic activity. Cancer Res 64 (14), 4931-4941.
17. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, et al. (2008). Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 68 (16), 6598-6607.
18. Carpinelli G, Bucci B, D'Agnano I, Canese R, Caroli F, Raus L, Brunetti E, Giannarelli D, Podo F, and Carapella CM (2006). Gemcitabine treatment of experimental C6 glioma: the effects on cell cycle and apoptotic rate. Anticancer Res 26 (4B), 3017-3024.
19. Kolfschoten GM, Pinedo HM, Scheffer PG, Schlüper HM, Erkelens CA, and Boven E (2000). Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynecol Oncol 76 (3), 362-368.
20. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, et al. (2009). mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15 (5), 1612-1622.
21. Lunt SJ, Kalliomaki TM, Brown A, Yang VX, Milosevic M, and Hill RP (2008). Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours. BMC Cancer 8, 2.
22. O'Reilly T, McSheehy PMJ, Kawai R, Kretz O, McMahon L, Brueggen J, Bruelisauer A, Gschwind HP, Allegrini PR, and Lane HA (2009). Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharm [Epub ahead of print].
23. Jain RK (2001). Normalizing tumour vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7, 987-989.
24. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, et al. (2000). Anti-vascular endothelial growth factor treatment augments tumour radiation response under normoxic or hypoxic conditions. Cancer Res 60, 5565-5570.
25. Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, and O'Dwyer PJ (2008). Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7 (4), 496-501.